TSH Biopharm Corporation Limited

TPEX:8432 Voorraadrapport

Marktkapitalisatie: NT$2.5b

TSH Biopharm Inkomsten in het verleden

Verleden criteriumcontroles 4/6

TSH Biopharm's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 15.8% per year. TSH Biopharm's return on equity is 7.1%, and it has net margins of 9.4%.

Belangrijke informatie

-0.7%

Groei van de winst

-0.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie18.5%
Inkomstengroei15.8%
Rendement op eigen vermogen7.1%
Nettomarge9.4%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Feb 18
Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

Jan 21
Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Dec 16
TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Opbrengsten en kosten

Hoe TSH Biopharm geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TPEX:8432 Opbrengsten, kosten en inkomsten (TWD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 249328833425
31 Mar 248679231025
31 Dec 238116231125
30 Sep 238385435335
30 Jun 238265535034
31 Mar 237655332333
31 Dec 227416229331
30 Sep 224506818014
30 Jun 224376017420
31 Mar 224325717121
31 Dec 214134716824
30 Sep 214314717232
30 Jun 214325317528
31 Mar 214184817729
31 Dec 204486218229
30 Sep 204425318932
30 Jun 204738319742
31 Mar 205038420547
31 Dec 195088520653
30 Sep 195028920059
30 Jun 194825218563
31 Mar 195035017891
31 Dec 185165817697
30 Sep 185216317397
30 Jun 1853673172100
31 Mar 185218517576
31 Dec 174866517274
30 Sep 174975817689
30 Jun 174754217989
31 Mar 1748598173110
31 Dec 16492141174116
30 Sep 16487165187121
30 Jun 16505176189120
31 Mar 16506127191106
31 Dec 1551483194106
30 Sep 155315919393
30 Jun 155465520199
31 Mar 155545921389
31 Dec 145627421386
30 Sep 145658119297
30 Jun 145829719693
31 Mar 1458510419493
31 Dec 1359711019587

Kwaliteitswinsten: 8432 has high quality earnings.

Groeiende winstmarge: 8432's current net profit margins (9.4%) are higher than last year (6.7%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 8432's earnings have declined by 0.7% per year over the past 5 years.

Versnelling van de groei: 8432's earnings growth over the past year (59.5%) exceeds its 5-year average (-0.7% per year).

Winst versus industrie: 8432 earnings growth over the past year (59.5%) exceeded the Pharmaceuticals industry -0.6%.

Rendement op eigen vermogen

Hoge ROE: 8432's Return on Equity (7.1%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y